503B is not 503A with a different letter. It's a different regulatory animal.
Published May 15, 2026 · Epioneum editorial · ~7 minute read
In 2012, a fungal meningitis outbreak traced to a single compounding pharmacy in Framingham, Massachusetts killed 64 people across 20 states. Congress responded the next year with the Drug Quality and Security Act, which carved compounding into two categories: 503A and 503B. The numbers sound like product codes. They are closer to two different rulebooks, and they decide who is legally allowed to ship the compounded semaglutide showing up in your monthly box.
The 2012 meningitis outbreak that wrote the law
The pharmacy at the center of the outbreak, the New England Compounding Center, was shipping pre-mixed steroid injections to hospitals across the country. Under the rules of the time, that was legally murky. Traditional compounding was meant for individual patients with individual prescriptions. NECC was running closer to a small drug manufacturer, with none of the FDA inspection cadence that drug manufacturers face.
The Drug Quality and Security Act of 2013 closed that gap by splitting the compounding world in two. Section 503A kept the traditional model intact: prescriptions, individual patients, state-board oversight. Section 503B created a new category called the “outsourcing facility,” which can produce in bulk without patient-specific prescriptions but has to register with the FDA and comply with current good manufacturing practice rules, the same cGMP framework that governs full pharma manufacturing.
The two-digit difference is the trade. 503A keeps the flexibility. 503B accepts the inspection.
503A is a pharmacy. 503B is something closer to a small manufacturer.
A 503A pharmacy is your neighborhood compounder, scaled. It operates under a state board of pharmacy, fills prescriptions written for named patients, and works from USP-NF substances or a defined bulk drug list. It can hold inventory, but only in limited quantities and against anticipated patient need. It does not get routine FDA inspection. There are tens of thousands of them operating across the US.
A 503B outsourcing facility is a different shape entirely. It registers annually with the FDA, submits to a cGMP inspection regime that looks more like pharmaceutical manufacturing than retail pharmacy, and can produce in batches without naming a patient on each unit. As of early 2026, the FDA’s public registered outsourcing facility list shows roughly 75 active 503B sites in the country. Three orders of magnitude smaller than the 503A pool.
Both categories can produce sterile injectables. Both can produce GLP-1 medications when the regulatory door is open. The door is what matters.
Why the shortage list changed everything for GLP-1
From 2022 through early 2025, semaglutide and tirzepatide sat on the FDA’s drug shortage list. Federal compounding law allows pharmacies and outsourcing facilities to produce essentially-copies of an FDA-approved drug while it is in shortage. That is the regulatory door that opened the compounded GLP-1 market. Telehealth providers built entire businesses on it.
The door started closing in late 2024. The FDA removed tirzepatide from the shortage list on October 2, 2024, reaffirmed that decision in December after a legal challenge, and finalized enforcement timelines that ran through Q1 2025. Semaglutide came off the shortage list on February 21, 2025, with enforcement against 503B facilities starting first and 503A pharmacies given a later runway.
For 503B outsourcing facilities, that effectively closed the standard-formulation business. Mass-producing a copy of a drug that is no longer in shortage runs straight into the “essentially-copies” rule the FDA enforces against outsourcing facilities. For 503A pharmacies, the picture stayed more complicated. The law still allows 503A compounding of a “personalized” version of an approved drug if a prescriber documents a specific clinical reason the commercial product will not work for the patient.
What 503A can still legally make in 2026, and what 503B can’t
In practice, this is why the compounded GLP-1 market did not collapse in 2025. It reshaped.
503B outsourcing facilities are largely out of the standard compounded semaglutide and tirzepatide business unless a renewed shortage opens the door again. Some pivoted to other molecules. Some shrank. A few continue producing GLP-1 variants that fall outside the FDA-approved formulation, where the “essentially-copies” rule does not apply.
503A pharmacies kept the broader playing field. A 503A compounder can still produce a “personalized” semaglutide formulation when the prescriber documents a clinical justification. In the telehealth GLP-1 market, the common forms are different strengths than the commercial pen, a different vehicle (vial vs. pen), or a combination product such as semaglutide with cyanocobalamin (B12) or low-dose niacinamide. The clinical justification has to be real, individual, and documented. How rigorous that documentation is in practice varies by provider and by pharmacy partner.
This is the part that matters for readers comparing programs. If your telehealth provider’s compounded semaglutide costs $139 a month and ships in a vial labeled with B12, you are almost certainly on a 503A combination product. If your provider says “from a US-licensed pharmacy” and gives you no further detail, you do not know which category you are buying from. Those are not the same purchase.
How to read what your telehealth provider is actually shipping you
Per Epioneum’s scoring methodology, pharmacy transparency is one of four axes that determine a provider’s Quality Score. The axis is graded on what the provider discloses, not on what they imply.
Level 2 of the axis is generic “licensed US pharmacy” language and no further detail. We score a lot of programs at this level. It is the minimum legal disclosure and the maximum marketing flexibility.
Level 3 is the provider naming the pharmacy partner type, 503A or 503B, without naming the specific facility. This is where the 503A vs 503B distinction becomes a consumer-protection question rather than a technicality. A program at level 3 is telling you something real about the inspection regime your medication came through.
Level 4 names the actual pharmacy and confirms LegitScript certification. Level 5 adds named medical leadership with a verifiable NPI and public facility addresses. Both are uncommon in the compounded GLP-1 segment. Both should be the floor for any program asking $300 or more a month.
The reader-side version of this is short. If the program will not put 503A or 503B in writing, the program is at level 2. If the program puts the pharmacy name in writing and the pharmacy is on the FDA’s registered outsourcing facility list, you have hard confirmation it is a 503B. If the pharmacy is not on that list, it is operating under 503A rules. The list is public and searchable.
What we still don’t know
There is no central registry of 503A pharmacies comparable to the FDA’s 503B list. State pharmacy boards regulate 503A facilities with widely varying inspection cadences. A 503A compounder in one state may face annual inspection. The same operation in another state may go three to five years between inspections.
There is also no public, peer-reviewed, lab-tested potency dataset for the compounded semaglutide market. A few small studies and one ISMP-flagged adverse-event review exist. None are large enough to draw confident comparisons between specific 503A pharmacies or between 503A and 503B output on this molecule. When we say a program lost a point on pharmacy transparency in our methodology, we are scoring disclosure. We are not, yet, scoring potency.
That gap is a real one. We flag it on every provider review where it applies. If lab-tested potency data becomes available at scale, the methodology page changes first.
Two pharmacies can ship the same molecule from the same active pharmaceutical ingredient supplier and operate under entirely different inspection regimes. That is the load-bearing fact behind the 503A vs 503B distinction. The question for a comparison-shopping reader is not which category is “better.” It is which category your provider is actually using, and whether they are willing to write it down.
If your current program will not tell you, that is information too.
This guide is informational only. It is not medical advice. Consult a US-licensed clinician before starting, changing, or stopping any GLP-1 medication. If you spot a factual error, corrections@epioneum.com.